177Lutetium-PSMA-617, the Newest Life-Prolonging Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate-specific membrane antigen (PSMA) is highly expressed by poorly differentiated, metastatic, and castration-resistant prostate cancer cells,1 creating a good imaging and therapeutic target. 177Lutetium (Lu) is a beta-emitting radionuclide that induces DNA strand breaks and cellular lethality.2 In the situation of 177Lu-PSMA-617, 177Lu is linked to a 617, which is a small molecule targeting vector that binds to PSMA. Once bound to the receptor on the target cell membrane, in this case, prostate cancer cell, the complex is internalized.3 Hence, the lethal radiopeptide is delivered internally to induce DNA breaks and eventual apoptosis.
Evan Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine
- Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Clinical Research Director, Genitourinary Oncology, Seattle Cancer Care Alliance
- Medical Director, Clinical Research Service, Fred Hutchinson Cancer Research Consortium
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.